The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best AI driven biotech stocks to invest in.

As of the June 5 close, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) had a strongly bullish consensus sentiment. Based on a 1-year target price of $88.14, the stock offers an upside potential of more than 167%% at the prevailing level. It received Buy ratings from all 8 analysts who provided coverage.

Copyright: nexusplexus / 123RF Stock Photo

On June 2, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) revealed that the company will be sharing data across 6 different presentations during the Endocrine Society’s Annual Meeting, ENDO 2026, in mid-June. Three of those presentations will be around PALSONIFY, which will incorporate data on long-term safety and efficacy from the open-label extension (OLE) studies, i.e., PATHFNDR-1 and PATHFNDR-2.

Besides that, there will be three presentations around the company’s atumelnant clinical development program. The company will share data from the Phase 2 study on congenital adrenal hyperplasia (CAH), along with Phase 1b/2a results for ACTH-dependent Cushing’s syndrome.

Back on May 15, Gavin Clark-Gartner from Evercore ISI reduced his target price for Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) from $89 to $88, resulting in an adjusted upside potential in excess of 167%. The firm maintained its Outperform rating on the stock.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.

While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.